期刊文献+

The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China 被引量:1

The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
下载PDF
导出
摘要 V-erb-a erythroblastic leukemia viral oncogene homolog 4(ERBB4) has been reported to be somatically mutated in 19% of melanoma cases.To investigate the prevalence of ERBB4 mutations in melanoma patients from southern China,we analyzed 117 formalin-fixed,paraffin-embedded melanoma samples archived in the Sun Yat-sen University Cancer Center.A matrix-assisted laser desorption/ionization time-of-flight mass spectrometry(MALDI-TOF MS) platform was used to screen for mutations.No ERBB4 hotspot mutations were detected.Our results indicate that ERBB4 mutations may play a limited role in melanomas in China;therefore,targeting the ERBB4 mutation in melanoma patients from southern China may not be a promising strategy. V-erb-a erythroblastic leukemia viral oncogene homolog 4 (ERBB4) has been reported to be somatically mutated in 19% of melanoma cases. To investigate the prevalence of ERBB4 mutations in melanoma patients from southern China, we analyzed 117 formalin-fixed, paraffin-embedded melanoma samples archived in the Sun Yat-sen University Cancer Center. A matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform was used to screen for mutations. No ERBB4 hotspot mutations were detected. Our results indicate that ERBB4 mutations may play a limited role in melanomas in China; therefore, targeting the ERBB4 mutation in melanoma patients from southern China may not be a promising strategy.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 2013年第7期410-414,共5页
  • 相关文献

参考文献10

  • 1Zhou OM, Li W, Zhang X, et al. The mutation profiles of common oncogenes involved in melanoma in southern China. J Invest Dermatol,2012,132:1935-1937.
  • 2Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011,364:2507 -2516.
  • 3Prickett TO, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet, 2009,41 :1127 -1132.
  • 4Dutton-Regester K, Irwin 0, Hunt P, et al. A high throughput panel for identifying clinically-relevant mutation profiles in melanoma. Mol Cancer Ther, 2012,11 :888-897.
  • 5Casula M, Muggiano A, Cossu A, et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer, 2009,9:352.
  • 6Veikkolainen V, Vaparanta K, Halkilahti K, et al. Function of ERBB4 is determined by alternative splicing. Cell Cycle, 2011,10:2647- 2657.
  • 7Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Bioi, 2009,21 :177-184.
  • 8Das PM, Thor AD, Edgerton SM, et al. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene, 2010,29:5214-5219.
  • 9Mill CP, Gettinger KL, Riese OJ 2nd. Ugand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res, 2011,317:392-404.
  • 10Williams EE, Trout W, Gallo RM, et aI. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor call lines. Cancer Lett, 2003,192:67- 74.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部